REG-Limitless Earth Plc: Investment in Nano Technology <Origin Href="QuoteRef">LMEL.L</Origin>

Limitless EarthAnnouncement

03/05/2016 07:05

3 May 2016

                              LIMITLESS EARTH PLC                              

                        ("Limitless" or the "Company")                         

                         Investment in Nano Technology                         

Limitless, an AIM quoted investing company, is pleased to announce that it has
invested US$300,000, approximately £200,000, by way of 8 per cent. convertible
senior notes, in Exogenesis Corporation ("Exogenesis"). This investment falls
within Limitless' strategy of investments driven by an aging population.

Exogenesis, founded in 2005 and based in Billerica, near Boston, Massachusetts
is a private nanotechnology company which has developed nanoscale surface
modification technology to, inter alia, improve the safety and efficacy of
implantable medical devices and is being used to develop next generation
microscopy tools for DNA analysis.

The Exogenesis technology is also being developed to produce next generation
integrated circuits and nanoelectronic devices.  Exogenesis has initiated
license agreements and strategic alliances with partners to commercialise its
technology in the fields of cardiovascular disease, orthopaedics, DNA
sequencing to enable personalised disease detection and next generation
semiconductor production for use in a variety of nanoelectronic devices.  It is
the opinion of Exogenesis that its proprietary surface modification
nanotechnology will enable more cost effective, safer and more efficacious
devices for healthcare and a variety of other fields.  In relation to its
surface modification technology, Exogenesis holds more than fifty granted
patents and more than thirty additional patent applications, in multiple
jurisdictions.

To date, Exogenesis has raised approximately US$25 million through a series of
investment rounds to develop its portfolio of technologies and applications.

Investment Terms

Limitless has invested US$300,000 (approximately £200,000,) in the Exogenesis
senior convertible notes which accrue an 8 per cent. annual interest
("Notes").  The Notes, together with accrued interest, are convertible into
Exogenesis series B preferred stock at a price of US$0.382 per share or, at the
option of Limitless, into Exogenesis series C preferred stock at a 20 per cent.
discount to the issue price at the time of the next financing.  Conversion of
the notes will occur at the earlier of a further fundraising round of not less
than US$5 million or 30 June 2017. Assuming conversion by Limitless into Series
B, on a fully diluted basis, considering all classes of common and preference
stock in issue, Limitless' investment represents approximately 1.0 per cent.
per cent of Exogenesis issued share capital and values Exogenesis at
approximately US$46 million.

In addition, the Company has been granted a warrant to purchase 10 per cent. of
the principal invested in additional series C preferred stock at a 20 per cent.
discount to the market price paid for the Series C preferred stock. The warrant
is valid for a period of one year following the first closing of the Series C
preferred stock fundraising.

The Notes are secured by the assets of Exogenesis including all patents and
patent applications.  Upon conversion into equity which will happen upon
Exogenesis closing its Series C financing, the security held by Limitless will
be granted equal voting rights with all other classes of stock, except as
provided by law, and conversion into common stock per terms of the Exogenesis
shareholders agreement.  Exogenesis preferred stock will automatically convert
into common stock in the event of further fundraising.

Guido Contesso, Director of Limitless, commented:  "The need for better and
more affordable healthcare has become critical. In industrialised economies,
aging populations are putting enormous strains on national healthcare systems,
and in emerging economies, population growth and a rising middle class are
creating enormous demand for medical care. Nanotechnology is playing an
increasingly important role in overcoming this global challenge including work
on nanoparticles for drug delivery which can deliver powerful medications to
exactly where they are needed in the body and making implantable medical
devices more safe and efficacious by modifying and improving the device
surfaces at a nanoscale level. The application of nanotechnology is also
enabling expensive laboratory analysis and diagnostic testing of DNA to be
performed on miniaturised chips, which can dramatically lower the costs and
improve quality of personalised medical data.  In the field of pharmaceutical
research, drug discovery is benefitting enormously from these
nanobiotechnology-based systems."

For further information, please contact:

Limitless Earth plc                                                    +44
(7780) 700 091     

Guido Contesso                                                         
www.limitlessearthplc.com      

Cairn Financial Advisers LLP                                  +44 (20) 7148
7900              

Nominated Adviser                                                    
www.cairnfin.com                              

Jo Turner/Tony Rawlinson                                        

Peterhouse Corporate Finance Limited                   +44 (20) 7469
0930              

Broker                                                                        
www.pcorpfin.com               

Peter Greensmith/Charles
Goodfellow                                               

About Limitless Earth plc

Limitless Earth plc is a proactive investment company that focuses on making
investments in and assisting companies which exhibit the potential to generate
returns through capital appreciation.  Limitless invests in small companies
where there are clear catalysts for value appreciation and the companies are
operating in sectors exhibiting long term growth linked to demographic change. 
Examples of such sectors include cleantech, life sciences, nanotech, medtech,
recycling, and new internet opportunities



END



Copyright © 2016 PR Newswire Association, LLC. All Rights Reserved